NASDAQ: SPRYArs Pharmaceuticals Inc Stock
$8.44-0.62 (-6.84%)
Updated Apr 18, 2024
SPRY Price
$8.44
Fair Value Price
$0.74
Market Cap
$814.47M
52 Week Low
$2.55
52 Week High
$11.27
P/E
-14.81x
P/B
3.53x
P/S
17,392.41x
PEG
N/A
Dividend Yield
N/A
Revenue
$30.00k
Earnings
-$54.37M
Gross Margin
100%
Operating Margin
-181,216.67%
Profit Margin
-181,216.7%
Debt to Equity
0.01
Operating Cash Flow
-$59M
Beta
0.99
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
SPRY Overview
Silverback Therapeutics Incoporated is a clinical-stage biopharmaceutical company that develops ImmunoTAC therapies targeting previously inaccessible disease pathways. Its tissue-targeted therapeutics treat chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B. Silverback Therapeutics was incorporated in 2016 and is headquartered in Seattle, WA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SPRY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SPRY ($8.44) is overvalued by 1,036.88% relative to our estimate of its Fair Value price of $0.74 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SPRY ($8.44) is not significantly undervalued (1,036.88%) relative to our estimate of its Fair Value price of $0.74 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SPRY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SPRY due diligence checks available for Premium users.
Be the first to know about important SPRY news, forecast changes, insider trades & much more!
SPRY News
Valuation
SPRY fair value
Fair Value of SPRY stock based on Discounted Cash Flow (DCF)
Price
$8.44
Fair Value
$0.74
Overvalued by
1,036.88%
SPRY ($8.44) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SPRY ($8.44) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SPRY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SPRY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-14.81x
Industry
15.68x
Market
41.33x
SPRY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.53x
Industry
5.76x
SPRY is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SPRY's financial health
Profit margin
Revenue
$0.0
Net Income
-$7.2M
Profit Margin
0%
SPRY's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
SPRY's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$233.2M
Liabilities
$2.4M
Debt to equity
0.01
SPRY's short-term assets ($231.73M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SPRY's short-term assets ($231.73M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SPRY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SPRY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$17.4M
Investing
$26.0M
Financing
$1.8M
SPRY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SPRY vs Biotech Stocks
Ars Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.